Ribocure Pharmaceuticals is a biotech company specializing in the development of RNA-based and oligonucleotide therapeutics.
Ribocure Pharmaceuticals has raised $33.0M in total funding. The most recent round was Undisclosed. The last funding was announced in July 2025.
Ribocure Pharmaceuticals's investors include Erik Selin, Jacob Torell.
Ribocure Pharmaceuticals is headquartered in Mölndal, Sweden.
Ribocure Pharmaceuticals is a biotech company specializing in the development of RNA-based and oligonucleotide therapeutics.
Ribocure Pharmaceuticals is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ribocure Pharmaceuticals — Funding & Investors." VCBacked, July 2, 2025, https://www.vcbacked.co/company/ribocure-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2025). Ribocure Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ribocure-pharmaceuticals
{{cite web |title=Ribocure Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/ribocure-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated